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Abstract
Background: Despite the successful inhibition of human immunodeficiency virus type 1 (HIV-1) replication by
combination antiretroviral therapy, cells latently infected with HIV-1 remaining in patients are a major obstacle for
eradication of HIV-1 infection. The tumor suppressor factor p53 is activated by HIV-1 infection, and restricts HIV-1
replication. However, a therapeutic strategy based on p53 activity has not been considered for elimination of
latently infected cells.
Methods: Apoptotic cells were analyzed using flow cytometry with anti-annexin A5-FITC Ab and PI staining
upon treatment of anticancer drugs. The expression and activation of p53 and apoptotic molecules in latently
HIV-1-infected T cells were compared using Western blot analysis. The role of p53 in the anticancer drug
treatment-induced apoptosis of cells latently infected with HIV-1 was determined by knock-down experiment
using siRNA against p53.
Results: Upon treatment with 5-fluorouracil (5-FU), apoptosis was increased in latently infected ACH2 cells encoding
competent p53 compared with uninfected parent A3.01 cells, while the apoptosis of latently infected p53 null J1.1
cells was less than that of uninfected cells. Treatment with 5-FU increased the levels of cleaved caspase-3 and
PARP in ACH2 cells compared with uninfected and latently infected p53 null J1.1 cells. The levels of expression and
activation of p53 were higher in both latently infected ACH2 and NCHA2 cells than in uninfected cells. Furthermore,
the activation levels of p53 in both cells were further increased upon 5-FU treatment. Consistent with p53 status,
apoptosis was markedly increased in ACH2 and NCHA2 cells compared with uninfected and latently infected J1.1
cells upon treatment with other anticancer drugs such as doxorubicin and etoposide. Inhibition of p53 in cells with
latent HIV-1 infection diminished apoptosis upon 5-FU treatment.
Conclusion: Evidence described here indicate that when treated with anticancer drugs, apoptosis of cells with latent
HIV-1 infection was increased via the p53 activation pathway and may provide information for application of
anticancer drugs to selectively eliminate HIV-1 reservoirs.
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Background
Persistent human immunodeficiency virus type 1 (HIV-1)
infection causes a progressive loss of CD4+ T cells,
followed by acquired immunodeficiency syndrome
(AIDS) [1, 2]. Although highly active antiretroviral
therapy (HAART) can improve the life-span of HIV-1
infected patients by successful suppression of the
HIV-1 replication, HAART is not able to eliminate
the latent reservoir established early during infection
[3]. Accordingly, latent reservoirs of HIV-1 infection
have importantly been recognized as a major barrier
to HIV-1 eradication [4, 5].
Numerous strategies for the elimination of latent HIV-
1 infection have been investigated. These strategies
include intensive ART regimens, transplantation of
CCR5-deleted bone marrow, and reactivation of HIV-1
expression. One of the most innovative strategies aims
to awaken the latent virus and thereby increase the kill-
ing of the latent infection reservoir by the immune
system, known as “shock and kill”, and uses T-cell acti-
vating cytokines (IL-7), T-cell receptor signaling pathway
activators (bryostatin and prostratin as a protein kinase
C activator), histone deacetylase inhibitors (valproic acid,
vorinostat (suberoylanilide hydroxamic acid)), DNA
methylase inhibitors, and disulfiram [6]. Although these
reactivating strategies have recently been shown to in-
crease viral RNA in patients, reduction of reservoir size
has not been consistently successful.
Tumor suppressor p53 plays a key role in the stimula-
tion of cell apoptosis and growth arrest through a co-
operative signaling network of genotoxic stress caused
by treatment with anticancer drugs, irradiation, ultravio-
let light, and glucose starvation [7]. HIV-1 infection also
induces genotoxic stresses linked to p53 activation in
CD4+ T cells by integration mediated- dsDNA strands
break, secretion of type I interferons and expression
of HIV-1 accessory proteins Vpr/Vpu, which may be
considered as intracellular markers of HIV-1 infection
[8–11]. The p53 activation by HIV-1 infection also
plays an important role in host-restriction mecha-
nisms against HIV-1 replication, which suppress long
terminal repeat (LTR)-mediated viral transcription
through Tat modulation [12].
With regard to apoptosis of HIV-l infected cells, an
earlier report showed that latently HIV-l infected H9,
J1.1 and U1 cells that are p53 null were more resistant
to apoptosis than their uninfected parent cells under
treatment with H2O2 and staurosporine (STS) which
leads to an increase in oxidative stress rather than
genotoxic stress [13]. In a recent study, ACH2 and U1
cells showed induction of HIV-1 reactivation by an alter-
native replication program (ARP) during cell apoptosis
after cytotoxic drug treatment [14]. Although these stud-
ies suggested that apoptosis might be an important
characteristic of latent HIV-1 infection, these data might
be missed by an examination of p53 status and compara-
tive analysis of the apoptotic ratio between the latently
infected and uninfected cells. Currently, the important
roles of p53 have been discussed in HIV-1 infection.
However, the p53-mediated apoptosis of latently infected
cells by treatment of anticancer drugs has not been con-
sidered in developing strategies for eliminating cells la-
tently infected with HIV-1. Herein, we hypothesize that
apoptosis may be more sensitively induced in latently in-
fected cells encoding competent p53 than uninfected
cells upon treatment with anticancer drugs. We found
that anticancer drugs greatly enhanced apoptosis of la-
tently infected cells compared with uninfected cells, and
knockdown of p53 significantly diminished the apop-
tosis. Our data suggest that anticancer drugs may be
useful agents for selectively purging HIV-1 reservoirs.
Methods
Cells, anticancer drugs and antibodies
A3.01 and cell lines latently infected with HIV-1 (A3.01-
derived ACH2 and Jurkat-derived J1.1) were obtained
from the NIH AIDS Research and Reference Reagent
Program. Latently infected A3.01-derived NCHA2 cells
were established in our laboratory [15]. Cells were cultured
as previously described [7]. Briefly, cells were maintained in
RPMI medium (Gibco-BRL) supplemented with 1 % L-
glutamine, 1 % penicillin–streptomycin, and 10 % (v/v)
heat-inactivated fetal bovine serum (FBS; Gibco-BRL) in an
incubator at 37 °C under an atmosphere of 5 % CO2. The
anticancer drugs, 5-fluorouracil (5-FU), doxorubicin, and
etoposide were purchased from Sigma-Aldrich (USA) and
treated with the concentrations indicated in previous
reports [16–19]. Antibodies (Ab) against caspase-3,
cleaved caspase-3, PARP, Bax, puma, phosphor-S15-
p53, and β-actin were obtained from Cell Signaling
Technology (USA). Anti-p53 antibodies (DO-1) were
obtained from Santa Cruz Biotechnology (USA).
Flow cytometric analysis of apoptosis
Early apoptotic (annexin A5-FITC-positive, propidium
(PI)-negative) and late apoptotic (annexin A5-FITC-
positive, PI-positive) cells were analyzed using flow cy-
tometry with anti-annexin A5-FITC Ab and PI staining
[20]. Briefly, cells treated with 5-FU for 24 h were then
incubated with anti-annexin A5-FITC Ab and PI (Cal-
biochem) for 10 min at room temperature. The stained
cells were detected using a FC500 flow cytometer and
analyzed with RXP1.0 software (Beckman Coulter). The
analysis of sub-G1 cell populations has been described
previously [19, 21]. Briefly, cells were incubated with
drugs for 36 h. Cells were then fixed with 70 % ice-cold
ethanol and incubated overnight at 4 °C. Fixed cells were
incubated with 100 μg RNase A at 37 °C for 1 h and
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stained with 50 μg/ml of PI. For measurement of
intracellular DNA content, at least 10,000 events were
analyzed. All experiments were performed independently
at least three times.
Western blot analysis
Western blot analysis was performed as previously de-
scribed [22]. Briefly, cells were treated with an antican-
cer drug, 5-FU, doxorubicin, or etoposide for 12 h and
then harvested in RIPA buffer (Cell Signaling Technol-
ogy) containing a complete EDTA-free protease and
phosphatase inhibitor cocktail (Roche). Forty μg of
protein extract was subjected to 10 % sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS–PAGE)
and transferred onto polyvinylidene difluoride mem-
branes (Millipore). The membranes were incubated with
appropriate antibodies and then visualized by chemilu-
minescence using Image Lab software (Bio-Rad) accord-
ing to the manufacturer’s protocols.
Knockdown and ectopic expression of p53
Five synthesized p53 siRNAs were purchased from Invi-
trogen. Their sequences were as follows: No. 1
(VHS40366): CCA UCC ACU ACA ACU ACA UGU
GUA A, No. 2 (VHS40367): CCA GUG GUA AUC UAC
UGG GAC GGA A, No. 3 (HSS110905): GCU UCG AGA
UGU UCC GAG AGC UGA A, No. 4 (HSS186390): GAG
UGG AAG GAA AUU UGC GUG UGG A, and No. 5
(HSS186391): CCG CCU GAG GUU GGC UCU GAC
UGU A. Knockdown of p53 was performed by electropor-
ation as described previously [12]. Briefly, 1 × 107 cells
were electroporated with 500 pmole of control siRNA (si-
con; Invitrogen) or p53 siRNAs in 0.4 cm cuvettes at
960 μF and 250 V. The ectopic expression of p53 in J1.1
cells was performed by electroporation using a Nucleofec-
tor™ kit X (Lonza) with 5 μg of pcDNA3- Flag-tagged p53
according to the manufacturer’s protocol [22].
Statistical analysis
The data are expressed as their mean value ± standard
deviation (SD). The data were compared using Student t
tests and p <0.05 was considered a significant difference.
Results
Distinct sensitivity of cells latently infected with HIV-1 to
apoptosis upon 5-FU treatment
Although numerous previous investigations have shown
apoptosis of cells infected with HIV-1, apoptosis of
latently infected cells is as yet little known. To address
this issue, we compared the apoptotic ratio between
latently infected cells and uninfected cells in the pres-
ence of anticancer drug-induced genotoxic stress. As
shown in Fig. 1a, using flow cytometry analysis, two cell
lines latently infected with HIV-1 (ACH2 and J1.1) and
an uninfected cell line (A3.01) all showed increased
apoptosis after treatment with 5-FU. Notably, we found
greatly increased apoptosis in latently infected ACH2
cells compared with other cells examined. However, the
other latently infected cells, J1.1, showed slightly de-
creased level of apoptosis in comparison with uninfected
A3.01 cells upon 5-FU treatment. These phenomena
were observed in both early and late apoptosis (Fig. 1a).
The proteolysis of caspase-3 and its substrate PARP
occurring in cells undergoing apoptosis was dramatically
increased in latently infected ACH2 cells by 5-FU treat-
ment, whereas proteolysis was barely detected in unin-
fected A3.01 and latently infected J1.1 cells (Fig. 1b).
These data indicate that after 5-FU treatment, cells la-
tently infected with HIV-1 have a distinctive cell fate
based on their distinct cellular machinery.
Tumor suppressor p53 is linked to the 5-FU treatment-
induced apoptosis of cells latently infected with HIV-1
Next, we sought to determine which cellular modulator
is associated with the distinctive fate of latently infected
cells during 5-FU-induced apoptosis. Previous studies
showed that p53 was activated in cells acutely infected
with HIV-1. Consistent with acute infection, the expres-
sion of p53 was increased in latently infected ACH2 cells
compared with their parent A3.01 cells. Notably, the
phosphorylation level of p53 was significantly enhanced
in ACH2 cells despite the lack of a specific stimulus,
which might be caused by latent infection-induced
stresses (Fig. 2a, upper panel). However, the expression
of p53 was not detected in latently infected J1.1 cells
originating from the Jurkat cell line that is known as p53
defective. Moreover, the increased levels of total and
phosphorylated p53 in ACH2 cells were further en-
hanced by 5-FU treatment compared with those in
A3.01 cells, while J1.1 cells showed no expression of p53
despite this stimulus (Fig. 2a, lower panel). To evaluate
p53-mediated cell apoptosis in latently infected cells
upon genotoxic stress, the molecules downstream of p53
in latently infected ACH2 and NCHA2 cells that express
the wild-type p53 were examined in the presence and
absence of 5-FU. The levels of expression of Bax, puma,
and p21 which are well known as p53 target genes, were
highly elevated together with the levels of p53 activation
in ACH2 and NCHA2 cells when cells were treated with
5-FU, while the increased levels were modest in unin-
fected cells (Fig. 2b). To confirm the p53-linked cell
apoptosis in latently infected cells, p53 null J1.1 cells
were ectopically expressed with p53 upon 5-FU treat-
ment. The cells ectopically expressed with p53 showed
increased apoptosis upon 5-FU treatment compared
with mock expression. Furthermore, the treatment of
the p53 inhibitor, pifithrin-α, in the cells showed dimin-
ished apoptosis compared with vehicle-treated J1.1 cells
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expressed with p53 (Fig. 2c). Unpredictably, the levels of
apoptosis induced by ectopic p53 expression were lower
than those of the p53 competent cells latently infected
with HIV-1. These data indicate that the cell fate linked
to apoptosis in cells latently infected with HIV-1 was
likely to be dependent on the status of p53 upon treat-
ment with anticancer drugs such as 5-FU.
Induced genotoxic stress and increased apoptosis of cells
latently infected with HIV-1 upon anticancer drug treatment
Anticancer drugs effectively promote cell apoptosis
linked to genotoxic stress inducing p53 activation. Given
this background, we sought to determine whether other
types of anticancer drugs can selectively induce p53-
mediated apoptosis of cells latently infected with HIV-1.
Anticancer drugs including etoposide and doxorubicin,
widely used in cancer therapy, were used to treat p53
competent ACH2 and NCHA2 cells as well as p53 null
J1.1 cells. In an analysis of sub-G1 DNA content, the
sub-G1 population of ACH2 and NCHA2 cells was
markedly increased in comparison with uninfected
A3.01 cells after etoposide or doxorubicin treatment
similarly with 5-FU treatment. Unlike p53 competent
cells, p53 null J1.1 cells showed slight resistance to
apoptosis (Fig. 3a). The p53 phosphorylation levels were
greatly increased in latently infected ACH2 and NCH2
cells in the presence of anticancer drugs in comparison
with uninfected cells, whereas J1.1 cells did not show
p53 expression after any drug treatment (Fig. 3b). These
findings suggest that apoptosis of cells latently infected
with HIV-1 might be induced by widely used anticancer












































































Fig. 1 5-FU treatment-induced apoptosis of cells latently infected with HIV-1. a The cells were treated with 5-FU at the indicated concentration
for 24 h. After treatment, the cells were measured using flow cytometry. The number of apoptotic cells is shown as a percentage in each plot
(upper panel). Total apoptotic cells are shown graphically with statistical analysis. The data are shown as mean ± SD (n = 3). **p <0.01 compared
with uninfected A3.01 cells (lower panel). b The cells were treated with 400 μM of 5-FU for 48 h, and then lysed with RIPA buffer.
Western blotting was used to analyze the protein levels from the cell lysates using antibodies against caspase 3, cleaved caspase 3,
PARP and β-actin as a loading control
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p53 plays a pivotal role in the anticancer drug-induced
increased apoptosis of cells latently infected with HIV-1
To determine whether p53 plays a key role in the anti-
cancer drug treatment-induced apoptosis of cells latently
infected with HIV-1, siRNA against p53 was introduced
into latently infected ACH2 and NCHA2 cells. The
levels of expression of p53 were efficiently diminished in
cells electroporated with No.1 p53 siRNA (Fig. 4a
upper), and the p53 knockdown with the chosen siRNA
was efficient in ACH2 and NCHA2 cells even upon 5-
FU treatment (Fig. 4a lower). The knockdown of p53 by
the siRNA significantly reduced the sub-G1 populations
of latently infected ACH2 and NCHA2 cells in the
presence of 5-FU (Fig. 4b), which may conceivably be
the result of disruption of the p53 downstream pathway,
triggering cell apoptosis. The role of p53 in the apoptosis
of these cells upon 5-FU treatment was further evi-
denced with the p53 inhibitor. As shown in Fig. 4c,
pifithrin-α treatment diminished cell apoptosis in both
the ACH2 and NCHA2 cells upon 5-FU treatment.
These data suggested that after anticancer drug
treatment, the latently infected cells were sensitive to
apoptosis via a p53 linked-pathway.
Discussion
During the clinical course of HIV-1 infection, latently
HIV-1 infected provirus is present in the long-lived CD4
+ T memory cells that play a role as a steady source of
infectious viral particles after interruption of treatment
and as a major obstacle to HIV-1 eradication [4, 5].
Eliminating such HIV-1 reservoirs is a great challenge,
because a selective marker by which to target the
reservoir latently infected with HIV-1 has not yet been
discovered.
HIV-1 infection can facilitate p53 expression and acti-
vation in T cells by integration-mediated host chromo-
somal abnormality and/or Vpr-induced DNA damaged-
stress and Vpu-mediated stabilization of p53 [8, 10, 11,
23]. The induced p53 may play roles in the host restric-
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Fig. 2 Expression of p53 and its downstream proteins in cells latently infected with HIV-1. a The expression levels of p53 and phosphorylated p53
at Ser 15 (p-p53) in latently infected and uninfected cells were measured in the absence (upper panel) or presence of 200 μM of 5-FU for 12 h
(lower panel). b The levels of expression of p53 and its downstream proteins were measured in latently infected ACH2 and NCHA2 upon treat-
ment of 200 μM of 5-FU for 24 h. c Western blotting was used to analyze the p53 and p-p53 levels in J1.1 cells electroporated with p53 expres-
sion plasmid upon 5-FU treatment (upper panel). Apoptosis of the cells was measured as Fig. 1a. Total apoptotic cells are shown graphically with
statistical analysis. The data are shown as mean ± SD (n = 3). *p <0.05, **p <0.01 compared with cells untreated with the drug
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acutely infected with HIV-1. Anticancer drugs such as
5-FU, doxorubicin, and etoposide are well known to
induce genotoxic stress linked to p53 activation
followed by cell apoptosis. Although important roles
for p53 in HIV-1 infection have been considered,
utilization of anticancer drugs to activate p53 and se-
lectively eliminate cells latently infected with HIV-1
has not been addressed.
In the present study, 5-FU induced the early and late
apoptosis of latently infected ACH2 cells compared with
latently infected J1.1 and uninfected A3.01 cells. More-
over, the levels of intracellular apoptotic markers such as
cleaved caspase-3 and PARP were markedly increased in
ACH2 cells compared with those in other cells (Fig. 1).
The uninfected A3.01 cells that is p53 competent also
showed significantly increased apoptosis upon 5-FU treat-
ment compared with that of p53 defective J1.1 cells, while
the levels were lower than those of the latently infected
ACH2 cells derived from A3.01 cells. These data reveal
that the differences in status of p53 among uninfected and
latently infected cells (Fig. 2a) may lead to p53 dependent
tendencies toward apoptosis upon genotoxic stress (Figs. 1,
2 and 3). Larrosa et al. showed that H9, J1.1, and U1 cells
latently infected with HIV-1 were resistant to cytotoxic
substances such as H2O2 and STP when compared with
their uninfected parent cells [13]. However, their findings
may do not support the resistance to apoptosis of latently
infected cells in general, because the cells they used were
all p53 null cell lines, which showed resistance to
apoptosis upon substance-induced stress. Consistent with
a previous report, our data also showed that p53 null J1.1
cells were more resistant to apoptosis upon genotoxic
stress than uninfected A3.01 (Figs. 1 and 3) and Jurkat
cells (data not shown). Together, these data indicate that
latent HIV-1 infection may prevent apoptosis of the host
cell to promote longer survival of the cells by an as yet
unknown mechanism in the absence of p53, but HIV-1
infection may facilitate the apoptosis of cells susceptible to
HIV infection that have competent p53. Although p53 is
known to be a key factor in inducing apoptosis in antican-
cer drug treated cells, the p53 null J1.1 cells still showed
small amounts of cell death. These data indicated that the
cells were undergoing apoptosis by the p53-independent
pathway such as p73 [24], Bid [25], MCL2 [26] and ATM/
E2F1 [27] that were showed in its parent Jurkat cells upon
the genotoxic stresses.
Western blot analysis of p53 target gene proteins
showed that the levels of Bax, puma, and p21, which are
the best-known p53 targets, were greatly increased in
latently infected cells expressing p53 upon 5-FU treat-
ment. As such, these gene products may contribute to
the sensitivity of cells to apoptosis. Although the 5-FU
treated A3.01 cells and the J1.1 cells expressed with
ectopic p53 also showed increased levels of apoptosis
compared with the untreated cells, the levels were much
weaker than those of the p53 competent cells infected
with HIV-1. The data indicated that the insufficient level
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Fig. 3 Anticancer drugs increased the death of cells latently infected with HIV-1. a Cells were treated with etoposide (5 μM) and doxycycline
(0.5 μM) for 36 h. The sub-G1 population (dead cells) of cells was determined by flow cytometry after PI staining (left panel). The data are shown
graphically with statistical analysis (right panel). The data are shown as mean ± SD (n = 3). *p <0.05, **p <0.01 compared with A3.01 cells. b Western
blotting was used to determine the levels of expression of p53 and p-p53 using appropriate antibodies under same conditions
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could not greatly increase apoptosis, as shown in the
ACH2 and NCHA2 cells. CD4+ T lymphocyte depletion
linked to HIV-1 infection has been explained by
numerous mechanisms including abortive infection-
induced pyroptosis [28], DNA-dependent protein kin-
ase [29], Fas-ligand [30], p53 activation [8] and viral
proteins Nef and Vpr [31, 32]. These observations
sufficiently explained the apoptosis as a result of
acute HIV-1 infection. Genini et al. suggested that
activation of p53 by acute HIV-1 infection may
contribute to the depletion of HIV-1 infected T cells [8].
The present data also showed that latently infected
cells, which are p53 competent, showed an increased
level of phosphorylated p53 and its target genes in
the absence of drugs, similarly to acute infection.
However, the slight enhancement of p53 activation in
the latently infected cells might not be sufficient to
trigger apoptosis. Accordingly, genotoxic stress in-
duced by anticancer drugs promoted the p53 activa-
tion synergistically leading to apoptosis of latently
infected cells.
Numerous anticancer drugs have been developed and
used for the cure of cancerous disease. Among them, 5-
FU, an inhibitor of thymine synthetase, doxorubicin, an
inhibitor of topoisomerase II, and etoposide, an inhibitor
of topoisomerase I, are widely used in the treatment of
cancers [33]. Although the drugs act on different en-
zymes linked to chromosomal DNA, these drugs com-
monly induce DNA stress followed by p53 activation-
induced apoptosis. Based on the mechanisms of action
of these drugs, 5-FU and doxorubicin/etoposide effi-
ciently induced p53 activation in latently infected cells,
followed by apoptosis, but not in p53 null J1.1 cells
(Figs. 1 and 3). A new generation of anticancer drug,
such as taxane, which inhibit the microtubule synthesis
during mitosis unlinked to DNA-damaging stress, are
used widely [34]. Therefore, p53-mediated apoptosis by
the drug should determine whether the drug selectively
induces the apoptosis of latently infected cells.
To determine the exact role of p53 in apoptosis of
latently infected cells upon treatment with an anticancer























































































Fig. 4 p53 knockdown diminished the death of cells latently infected with HIV-1. a Five p53 siRNAs were individually introduced into A3.01 cells
using electroporation. After 48 h, Western blotting was used to determine the levels of expression of p53 (upper panel). Western blotting was
used to determine the knockdown effect of p53 siRNA (No. 1) in latently infected cells (ACH2 and NCHA2) upon 5-FU treatment (lower panel). b
The p53 in these cells was knocked down with p53 siRNA (No. 1) were treated with 5-FU (200–400 μM) for 36 h. The sub-G1 population was
determined using flow cytometry. Total apoptotic cells are shown graphically with statistical analysis. The data are shown as mean ± SD (n = 3).
*p <0.05 compared with cells electroporated with con. siRNA cells. c The cells were treated with 5-FU in the presence or absence of pifithrin-α for
48 h, and the apoptosis levels were then determined using flow cytometry. Apoptotic cells are shown graphically with statistical analysis. The data
are shown as mean ± SD (n = 3). **p <0.01 compared with cells treated with the vehicle
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Both could reduce the apoptosis of the cells upon 5-FU
treatment. The diminished apoptosis in the ACH2 and
NCHA2 cells by p53 siRNA and the inhibitor indicated
that p53 played an important role in the anticancer
drug-induced apoptosis (Fig. 4). However, the siRNA
and the inhibitor could not completely reduce the apop-
tosis. The results might have been caused by the p53-
independent pathways and the incomplete efficacy of the
siRNA and the inhibitor. A mechanism underlying viral
reactivation in response to anticancer drugs has been
proposed [14]. However, the data presented did not
show distinctive apoptotic fates between cells because
they focused on viral reactivation in the reservoir
cells during anticancer drug-induced apoptosis with-
out comparison to uninfected parent cells or assessing
p53 status.
Although several methodologies for isolation of la-
tently infected cells ex vivo have been developed, study-
ing the functional role of those cells is so far difficult.
There are lot of hurdles, such as the rarity of reservoirs
(<1 per 106 CD4+ T cells), the absence of suitable
markers by which to isolate cells and T-cell activator
treatments for surmounting the rarity, which may acti-
vate a variety of cellular signals [35]. Therefore, evalu-
ation of p53-mediated apoptosis of latently infected cells
in vivo and ex vivo remains for further study.
Conclusions
We conclude that anticancer drugs may be useful agents
for selectively purging HIV-1 reservoirs and might con-
tribute to insights for future therapeutic strategies to
promote complete viral eradication.
Acknowledgments
We are grateful to the AIDS Research and Reference Reagent Program
(ARRRP, NIH, USA) for providing cell lines (A3.01, ACH2, Jurkat and J1.1 cells).
Funding
This work was supported by intramural grants from the Korea National
Institute of Health (Grant Number: 2013-N51002-00 and 2016-NG51002-00).
Availability of data and material
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
C-HY conceived the project and designed experiments. YS mainly conducted
the experiments. C-HY, YS, HL, B-SC, K-CK, CK, Y-SB participated in the
experimental design and the drafting of the manuscript. All authors read
and approved the final manuscript.
Competing interests
The authors have declared that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Division of AIDS, Center for Immunology and Pathology, Korea National
Institute of Health, 187 Osongsaengmyeong 2-ro, Osong-yeup, Cheongju,
Chungbuk 363-951, South Korea. 2Department of Biological Sciences,
Sungkyunkwan University, Suwon, Republic of Korea.
Received: 4 May 2016 Accepted: 5 August 2016
References
1. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF.
Experimental approaches to the study of HIV-1 latency. Nat Rev
Microbiol. 2007;5(2):95–106.
2. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;
1(1):a007096.
3. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding
HIV-1 latency provides clues for the eradication of long-term reservoirs.
Nat Rev Microbiol. 2009;7(11):798–812.
4. Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward
eradication. Drug Discov Today. 2013;18(11–12):541–51.
5. Siliciano JD, Siliciano RF. Recent developments in the search for a cure for
HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin
Immunol. 2014;134(1):12–9.
6. Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Sogaard OS.
Eliminating the latent HIV reservoir by reactivation strategies: advancing to
clinical trials. Hum Vaccin Immunother. 2013;9(4):790–9.
7. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor:
anti-apoptotic p53. Cell Death Differ. 2008;15(6):959–76.
8. Genini D, Sheeter D, Rought S, Zaunders JJ, Susin SA, Kroemer G, et al. HIV
induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated
mechanism. FASEB J. 2001;15(1):5–6.
9. Imbeault M, Lodge R, Ouellet M, Tremblay MJ. Efficient magnetic bead-
based separation of HIV-1-infected cells using an improved reporter virus
system reveals that p53 up-regulation occurs exclusively in the virus-
expressing cell population. Virology. 2009;393(1):160–7.
10. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-
mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem.
2003;278(28):25879–86.
11. Verma S, Ali A, Arora S, Banerjea AC. Inhibition of beta-TrcP-dependent
ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in
human T cells. Blood. 2011;117(24):6600–7.
12. Yoon CH, Kim SY, Byeon SE, Jeong Y, Lee J, Kim KP, et al. p53-derived host
restriction of HIV-1 replication by protein kinase R-mediated Tat
phosphorylation and inactivation. J Virol. 2015;89(8):4262–80.
13. Fernandez Larrosa PN, Croci DO, Riva DA, Bibini M, Luzzi R,
Saracco M, et al. Apoptosis resistance in HIV-1 persistently-infected
cells is independent of active viral replication and involves
modulation of the apoptotic mitochondrial pathway. Retrovirology.
2008;5:19.
14. Khan SZ, Hand N, Zeichner SL. Apoptosis-induced activation of HIV-1 in
latently infected cell lines. Retrovirology. 2015;12:42.
15. Kim KC, Kim HG, Roh TY, Park J, Jung KM, Lee JS, et al. The effect of CD4
receptor downregulation and its downstream signaling molecules on HIV-1
latency. Biochem Biophys Res Commun. 2011;404(2):646–51.
16. Pan X, Zhang X, Sun H, Zhang J, Yan M, Zhang H. Autophagy
inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS
formation in human non-small cell lung cancer A549 cells. PLoS One.
2013;8(2):e56679.
17. Qi Z, Li Y, Hu J, Guo H, Zhao X, Wang G, et al. The DG75 B-cell lymphoma
line exhibits biclonal immunoglobulin gene rearrangement. Biomed Rep.
2013;1(1):111–4.
18. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, et al. TLR3
induction by anticancer drugs potentiates poly I:C-induced tumor cell
apoptosis. Cancer Sci. 2010;101(7):1610–7.
19. Yoon CH, Lee ES, Lim DS, Bae YS. PKR, a p53 target gene, plays a crucial
role in the tumor-suppressor function of p53. Proc Natl Acad Sci U S A.
2009;106(19):7852–7.
20. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, et al.
5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular
oxidative stress. J Exp Clin Cancer Res. 2012;31:60.
Shin et al. Virology Journal  (2016) 13:141 Page 8 of 9
21. Lee ES, Yoon CH, Kim YS, Bae YS. The double-strand RNA-dependent
protein kinase PKR plays a significant role in a sustained ER stress-induced
apoptosis. FEBS Lett. 2007;581(22):4325–32.
22. Kim HY, Choi BS, Kim SS, Roh TY, Park J, Yoon CH. NUCKS1, a novel Tat
coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated
viral transcription on the HIV-1 LTR promoter. Retrovirology. 2014;11:67.
23. Imbeault M, Ouellet M, Tremblay MJ. Microarray study reveals that HIV-1
induces rapid type-I interferon-dependent p53 mRNA up-regulation in
human primary CD4+ T cells. Retrovirology. 2009;6:5.
24. Freebern WJ, Smith JL, Chaudhry SS, Haggerty CM, Gardner K. Novel cell-
specific and dominant negative anti-apoptotic roles of p73 in transformed
leukemia cells. J Biol Chem. 2003;278(4):2249–55.
25. Karpinich NO, Tafani M, Schneider T, Russo MA, Farber JL. The course of
etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. J Cell
Physiol. 2006;208(1):55–63.
26. Aresvik DM, Pettersen RD, Abrahamsen TG, Wright MS. 5-fluorouracil-
induced death of Jurkat T-cells–a role for caspases and MCL-1.
Anticancer Res. 2010;30(10):3879–87.
27. Ahmadianpour MR, Abdolmaleki P, Mowla SJ, Hosseinkhani S. Gamma
radiation alters cell cycle and induces apoptosis in p53 mutant E6.1 Jurkat
cells. Appl Radiat Isot. 2013;71(1):29–33.
28. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell
death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature.
2014;505(7484):509–14.
29. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ.
HIV-1 causes CD4 cell death through DNA-dependent protein kinase during
viral integration. Nature. 2013;498(7454):376–9.
30. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, et al. Peak SIV replication
in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells.
Nature. 2005;434(7037):1148–52.
31. Fevrier M, Dorgham K, Rebollo A. CD4+ T cell depletion in human
immunodeficiency virus (HIV) infection: role of apoptosis. Viruses.
2011;3(5):586–612.
32. Varbanov M, Espert L, Biard-Piechaczyk M. Mechanisms of CD4 T-cell
depletion triggered by HIV-1 viral proteins. AIDS Rev. 2006;8(4):221–36.
33. Swift LH, Golsteyn RM. Genotoxic anti-cancer agents and their relationship
to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer
cells. Int J Mol Sci. 2014;15(3):3403–31.
34. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev
Cancer. 2004;4(4):253–65.
35. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB,
et al. Analysis of human immunodeficiency virus type 1 gene expression
in latently infected resting CD4+ T lymphocytes in vivo. J Virol.
2003;77(13):7383–92.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shin et al. Virology Journal  (2016) 13:141 Page 9 of 9
